# OnCo record paper-keynote-716-lancet-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-keynote-716-lancet-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-keynote-716-lancet-2022" ;
  schema:name "KEYNOTE-716: adjuvant pembrolizumab versus placebo in completely resected stage IIB or IIC melanoma"@en ;
  schema:description "A year of pembrolizumab after surgery for stage IIB or IIC melanoma reduced recurrences and distant metastases by about 35 to 40 percent, extending adjuvant immunotherapy to node-negative but thick or ulcerated melanomas."@en ;
  schema:url <https://onco.cc/key-papers/paper-keynote-716-lancet-2022/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(22)00562-1>, <https://pubmed.ncbi.nlm.nih.gov/35367007/> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(22)00562-1> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Luke JJ, Rutkowski P, Queirolo P, et al." ;
  onco:cancers <https://onco.cc/cancers/stage-ii-melanoma/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:trials <https://onco.cc/trials/keynote-716/> ;
  onco:journals <https://onco.cc/journals/lancet/> .